Chinese maker of low-cost quadrupeds and the G1/H1/R1 humanoids; listed on Shanghai's STAR Market in Aug 2026, the first humanoid-robot stock on the A-share market.
Unitree began trading on Shanghai's STAR Market on 19 August, rising as much as ~630% intraday and closing up ~460% at 845 yuan, a valuation near $50B. It is the first humanoid-robot maker to list anywhere — though most of its revenue still comes from quadrupeds and components, and the shares gave back much of the debut gain within days.
Unitree Robotics — Shanghai STAR Market (688836) — Unitree began trading on Shanghai's STAR Market on 19 Aug 2026, the first humanoid-robot maker to reach a public market anywhere. The stock rose as much as ~630% intraday and closed the debut up ~460% at 845 yuan, valuing the company near $50B — an order of magnitude above the ~$7B private mark set months earlier. Unitree's revenue still comes mostly from quadrupeds and components rather than humanoids, and the shares gave back a large part of the debut gain in the following days; the milestone is the listing itself, not the price.
Smart Analytics Global puts H1 2026 global humanoid shipments at 19,100 units, up 272% year over year. AgiBot shipped about 8,400 for a 44% share, passing Unitree's ~5,900 and 31%. Chinese vendors account for 97% of units shipped and Chinese buyers for 85% of demand.
DeepSeek put ¥140.8M ($20.8M) into Unitree's Shanghai IPO as a strategic placement — 933,399 shares, 2.31% of the placement — alongside an agreement to jointly develop AI models for humanoid robots. Unitree gives DeepSeek preference for model-training services; DeepSeek gives Unitree preference when buying robots.
Unitree priced its STAR Market listing at ¥150.80 a share, raising about ¥6.1B ($904M) from 40.4 million shares — 10% of enlarged capital. The July prospectus had planned ¥4.2B at a ¥42B valuation floor; bids during the inquiry implied as much as ¥55B. It would be the mainland's first listed humanoid robot maker.
The Trump administration, via an FCC order after an interagency national-security review, barred imports of new Chinese humanoid and quadruped robots (and grid/data-center power inverters), citing risks of disruption, data theft and cyberattacks to the US AI supply chain. It reshapes the humanoid market just as Chinese makers were sweeping global funding and deployment rankings.
In a Nature-published preclinical trial, teleoperated Unitree G1 humanoids removed gallbladders from live pigs — a world first for humanoid robots in surgery, using standard surgical tools under full human control, with recalibration and latency still limiting.
China's securities regulator cleared Unitree's registration for a ~¥4.2B ($618M) STAR Market IPO — at least 40.4M shares (~10%), implying a ~$6.2B valuation, with a debut possible as early as late July.
Alibaba-affiliate Ant Group led a 500M yuan (~$74M) round in robotics firm Zeroth — its 12th humanoid-sector deal since early 2025, a portfolio spanning Unitree, Galaxea and parts/software startups, plus its own RobbyAnt subsidiary.
Neubility signed a strategic-partnership MOU with Unitree to co-develop industrial robot solutions, pairing Neubility's autonomous-navigation platform with Unitree's robot hardware.
GMO started selling Unitree humanoid robots in Japan — a new commercial channel.
No coverage matches this filter yet.
AgiBot (Zhiyuan) 
DeepSeek